Evidence map›Paper›PMID 36561188›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection.

Yarden Golan, Mikias Ilala, Caryl Gay, Soumya Hunagund, Christine Y Lin, Arianna G Cassidy, Unurzul Jigmeddagva, Lin Li, Nida Ozarslan, Ifeyinwa V Asiodu and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yarden GolanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America.
Mikias IlalaDepartment of Pediatrics, University of California, San Francisco, California, United States of America.
Caryl GayDepartment of Family Health Care Nursing, University of California, San Francisco, California, United States of America.
Soumya HunagundDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Christine Y LinDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Arianna G CassidyDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Unurzul JigmeddagvaCenter for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Lin LiDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Nida OzarslanDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Ifeyinwa V AsioduDepartment of Family Health Care Nursing, University of California, San Francisco, California, United States of America.
Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America.
Valerie J FlahermanDepartment of Pediatrics, University of California, San Francisco, California, United States of America.
Stephanie L GawDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Mary PrahlDepartment of Pediatrics, University of California, San Francisco, California, United States of America.
University of California, San Francisco · US

Funding

The Immunologic Impact of In Utero Malaria Exposure and Prenatal ChemopreventionK23AI127886 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRAHL, MARY · 2017 to 2021
$1.0M
Placental malaria: The role of inflammation at the maternal-fetal interfaceK08AI141728 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GAW, STEPHANIE LINA · 2019 to 2023
$950k
NIAID NIH HHS K08 AI141728NIAID NIH HHS K23 AI127886
6 · The paper itself

Abstract

Anti-SARS-CoV-2 antibodies have been found in human-milk after COVID-19 infection and vaccination. However, little is known about their persistence in milk after booster vaccination and breakthrough infection. In this study, human-milk, saliva and blood samples were collected from 33 lactating individuals before and after mRNA-based vaccination and COVID-19 breakthrough infections. Antibody levels were measured using ELISA and symptoms were assessed using questionnaires. Evaluation of maternal and infant symptomatology revealed that infected mothers reported more symptoms than vaccinated mothers. We found that after vaccination, human-milk anti-SARS-CoV-2 antibodies persisted for up to 8 months. In addition, distinct patterns of human milk IgA and IgG production we observed after breakthrough infection compared to 3-dose vaccination series alone, indicating a differential central and mucosal immune profiles in hybrid compared with vaccine-induced immunity. To investigate passively-derived milk antibody protection in infants, we examined the persistence of these antibodies in infant saliva after breastfeeding. We found that IgA was more abundant in infant saliva compared to IgG and persist in infant saliva longer after feeding. Our results delineate the differences in milk antibody response to vaccination as compared to breakthrough infection and emphasize the importance of improving the secretion of IgA antibodies to human milk after vaccination to improve the protection of breastfeeding infants.

Identifiers

PMID36561188
PMCPMC9774223
OpenAlexW4312214609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.